Related Experiment Video

Updated: Mar 25, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Recent advances in management of the HIV/HCV coinfected patient

Cindy J Bednasz1, Joshua R Sawyer2, Anthony Martinez3

  • 1School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA.

Future Virology
|February 16, 2016
PubMed

Insights

Direct-acting antiviral agents have improved hepatitis C virus (HCV) treatment. This review focuses on pharmacotherapy for individuals coinfected with HIV and HCV, addressing their unique treatment needs.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacotherapy

Background:

  • Chronic hepatitis C virus (HCV) infection is a global health issue affecting millions.
  • HCV/HIV coinfection accelerates liver disease progression, increasing risks of liver failure and mortality, especially with uncontrolled HIV.
  • Recent advancements in direct-acting antiviral agents (DAAs) have revolutionized HCV treatment.

Purpose of the Study:

  • To review current pharmacotherapy strategies for HIV/HCV coinfected individuals.
  • To discuss the evolving treatment landscape for coinfected patients.
  • To highlight key considerations in managing coinfection.

Main Methods:

  • Literature review of recent studies on HCV treatment in coinfected populations.
  • Analysis of pharmacotherapy guidelines and clinical trial data.
  • Synthesis of information on efficacy, safety, and drug interactions.

Main Results:

  • DAAs offer shorter treatment durations, higher efficacy, and fewer adverse events for HCV.
  • Expanding treatment options are now available for the HIV/HCV coinfected population.
  • Effective HIV management is crucial for optimizing HCV treatment outcomes.

Conclusions:

  • Pharmacotherapy for HCV has significantly advanced, benefiting coinfected individuals.
  • Tailored treatment approaches are essential for managing HIV/HCV coinfection.
  • Continued research is needed to optimize long-term outcomes.

Keywords:
HCVHIVdirect-acting antiviralnull responderrelapsesustained virologic response

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.5K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
475
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
616
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
316